|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The TM6SF2 E167K substitution promotes steatosis and lipid abnormalities in part by altering TM6SF2 and microsomal triglyceride transfer protein expression and differentially impacts CHC and chronic hepatitis B viral load, while effects on fibrosis are marginal.(Hepatology 2016;64:34-46).
|
26822232 |
2016 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In HIV/HCV coinfection the TM6SF2 E167K variant is an independent predictor of severe fibrosis, but appears to be independently associated with severe steatosis only for patients with a non-3 HCV genotype.
|
27784963 |
2016 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Associations of the single nucleotide polymorphisms (SNP) PNPLA3 rs738409 and TM6SF2 rs58542926 with hepatic steatosis have recently been established.
|
26847197 |
2016 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, IL28B rs12979860 and PNPLA3 rs738409 modify steatosis.
|
26259026 |
2016 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 C > G single nucleotide polymorphism (SNP) has been associated with steatosis and fibrosis in previous NAFLD populations in which cirrhotic patients were very poorly represented.
|
27150500 |
2016 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
|
26745555 |
2016 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, PNPLA3 rs2294918 E434K decreased PNPLA3 expression, lessening the effect of the I148M variant on the predisposition to steatosis and liver damage.
|
26605757 |
2016 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Associations of the single nucleotide polymorphisms (SNP) PNPLA3 rs738409 and TM6SF2 rs58542926 with hepatic steatosis have recently been established.
|
26847197 |
2016 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PNPLA3 rs738409 G allele carriers were found to be more susceptible to the metabolic-related hepatic steatosis, and developed NAFLD and liver fibrosis despite presenting relatively better metabolic statuses and lower risks for carotid atherosclerosis.
|
26765961 |
2016 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The I148M variant has a strong impact on the full spectrum of liver damage related to fatty liver, encompassing non-alcoholic steatohepatitis, advanced fibrosis, and hepatocellular carcinoma, and influences the response to therapeutic approaches.
|
26409295 |
2016 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PNPLA3 rs738409 (C>G) was associated with the risk of both advanced liver fibrosis and steatosis in patients with CHC, especially among Caucasian populations.
|
26419236 |
2016 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In 100 treated patients matched 1:1 for modality of recruitment, gender, presence of IFG or type 2 diabetes, PNPLA3 I148M risk alleles, TM6SF2 E167K variant, age, and BMI, statin use remained associated with protection from steatosis (OR 0.09, 95% C.I.
|
25980762 |
2015 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This is the first demonstration that TM6SF2 E167K variant is an independent predictor of liver steatosis in chronic hepatitis C.
|
25581573 |
2015 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TM6SF2 E167K variant impacts on steatosis severity and is associated with liver damage and fibrosis in patients with CHC.
|
25820484 |
2015 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Carriers of the TM6SF2 E167K variant have fatty liver as a result of reduced secretion of very-low-density lipoproteins (VLDLs).
|
25251399 |
2015 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A discrete trait analysis of NAFLD showed that rs58542926 was associated with a modest risk of fatty liver (P = 0.038; odds ratio [OR]: 1.37; 95% confidence interval [CI]: 1.02-1.84); nevertheless, conditioning on patatin-like phospholipase domain-containing 3 (PNPLA3)-rs738409 abolished this effect.
|
25302781 |
2015 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The rs738409 polymorphism was only significantly associated with risk of simple steatosis in the allele contrast and had no effect in the other genetic models.
|
25791171 |
2015 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The PNPLA3 rs738409 variant influences histological liver damage in Japanese patients with chronic hepatitis C. The G allele homozygotes are at higher risk for hepatic steatosis, severe necroinflammation, and advanced fibrosis.
|
25543233 |
2015 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A genetic variant in adiponutrin (PNPLA3) gene, rs738409 C/G, is associated with steatosis, severity, and progression of liver fibrosis in CHC patients, and predicts treatment outcome in difficult-to-cure HCV-infected patients with advanced fibrosis.
|
26389885 |
2015 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection.
|
26599080 |
2015 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The genetic polymorphism with an isoleucine-to-methionine substitution at position 148 (rs738409 C>G) in the patatin-like phospholipase domain protein 3 (PNPLA3) gene confers risk of steatosis.
|
25964223 |
2015 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A discrete trait analysis of NAFLD showed that rs58542926 was associated with a modest risk of fatty liver (P = 0.038; odds ratio [OR]: 1.37; 95% confidence interval [CI]: 1.02-1.84); nevertheless, conditioning on patatin-like phospholipase domain-containing 3 (PNPLA3)-rs738409 abolished this effect.
|
25302781 |
2015 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our aim was to assess the impact of PNPLA3 rs738409 G-allele on steatosis in HCV patients.
|
24927606 |
2015 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The G-allele of PNPLA3 rs738409 was associated with NAFLD (odds ratio [OR] 1.55, 95% confidence interval 1.13-2.11, P = 0.006) and moderate-to-severe steatosis (OR 3.77, 95% confidence interval 1.78-7.98, P = 0.001) adjusted for age, sex, and BMI standard deviation score.
|
25522307 |
2015 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The protective effect of statins on steatohepatitis was stronger in subjects not carrying the I148M PNPLA3 risk variant (p=0.02 for interaction), as statins were negatively associated with steatohepatitis in patients negative (p<0.001), but not in those positive for the I148M variant (p=n.s.).
|
25980762 |
2015 |